Metastatic Triple Negative Breast Cancer (O’Shaughnessy) Question Title * 1. 1. In the phase 3 Study 301 trial comparing eribulin with capecitabine, eribulin did not significantly improve OS or PFS in the TNBC subgroup. True False Question Title * 2. 2. The phase 3 TNT trial demonstrated that patients with BRCA1/2-mutated triple-negative breast cancer who received carboplatin achieved a doubling of response rate and a significantly longer PFS compared to docetaxel. True False Next